Hamdan Medical Journal (previously the Journal of Medical Sciences)
|Table of Contents|
Suppression of Premature Stop Codons for the Treatment of a Subset of Patients with Genetic Disorders
The concept of personalized medicine has been extended to recognize the fact that variations in the genetic makeup of individuals can greatly alter their responsiveness to drug treatments for a variety of disorders. An important corollary to this concept is that patients may have one of a number of different genetic diseases due to the same type of mutation in the disease-causing gene. This creates the possibility of a very different paradigm within personalized medicine, in which a drug can be designed to treat a specific genetic mutation, rather than a specific disease. The first example of this paradigm is drug-based suppression of a premature stop codon. There are a large number of individuals collectively afflicted by genetic disorders resulting form premature stop codons. Development of a drug-based therapy that can suppress this class of mutations could allow treatment of subsets of patients across a large number of genetic disorders, and thus address a substantial unmet medical need.
Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 2001; 107: 411-4.
Culbertson MR. RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet 1999; 15: 74-80.
Dent KM, Dunn OM, von Niederhausem AC, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005; 134: 295-8.
Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997; 1: 35-9.
Singh A, Ursic D, Davies J. Phenotypic suppression and misreading Saccharomyces cerevisiae. Nature 1979; 277: 146-8.
Palmer E, Wilhelm JM, Sherman F. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 1979; 277: 148-9.
Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985; 13: 6265-72.
Trecartin RF, Liebhaber SA, Chang JC, Lee KY, Kan YW. Beta zero thalassemia in Sardinia is caused by a nonsense mutation. J Clin Invest 1981; 68: 1012-7.
Chang JC, Kan YW. beta 0 thalassemia, a nonsense mutation in man. Proc Natl Acad Sci USA 1979; 76: 2886-9.
Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-9.
Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3: 1280-4.
Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104: 375-81.
Buvoli M, Buvoli A, Leinwand LA. Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse. PLoS ONE 2007; 2(5): e427.
Kaufman RJ. Correction of genetic disease by making sense from nonsense. J Clin Invest 1999; 104: 375-81.
Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002; 27: 619-27.
James PD, Raut S, Rivard GE, et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106: 3043-8.
Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001; 10: 291-9.
Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002; 80: 367-76.
Sleat DE, Sohar I, Gin RM, Lobel P. Aminoglycoside- mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001; 5 Suppl A: 57- 62.
Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTRRG542X transgene. J Mol Med 2002; 80: 595-604.
Grayson C, Chapple JP, Willison KR, Webster AR, Hardcastle AJ, Cheetham ME. In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients. J Med Genet 2002; 39: 62-7.
Helip-Wooley A, Park MA, Lemons RM, Thoene JG. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 2002; 75: 128-33.
Bidou L, Hatin I, Perez N, Allamand V, Panthier JJ, Rousset JP. Premature stop codons involved in muscular dystrophies show a broad spectrum of read through efficiencies in response to gentamicin treatment. Gene Ther 2004; 11: 619-27.
Hein LK, Bawden M, Muller VJ, Sil1ence D, Hopwood JJ, Brooks DA. alpha-L-iduronidase premature stop codons and potential readthrough in mucopolysaccharidosis type I patients. J Mol Biol 2004; 338: 453-62.
Howard MT, Anderson CB, Fass U, et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004; 55: 422-6.
Lai CH, Chun HH, Nahas SA, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA 2004; 101: 15676-81.
Loufrani L, Dubroca C, You D, et al. Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler. Thromb Vasc Biol 2004; 24: 671-6.
Sangkuhl K, Schulz A, Rompler H, Yun J, Wess J, Schoneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 2004; 13: 893-903.
Clancy JP, Sebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 1683-92.
Wilschanski M, Famini C, Blau H, et al. Pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000; 161: 860-5.
Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin- induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Eng J Med 2003; 349: 1433-41.
Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003; 22: 15-21.
Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49: 706-11.
Kohlhepp SJ, Loveless MO, Kohnen PW, Houghton DC, Bennett WM, Gilbert DN. Nephrotoxicity of the constituents of the gentamicin complex. J Infect Dis 1984; 149: 605-14.
Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447(7140): 87-91
Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47: 430-44.